Mangoceuticals, Inc.  announced the highly anticipated release and availability of ?PRIME? by MangoRx, Powered by Kyzatrex® (?PRIME?) bringing the FDA-approved oral testosterone replacement therapy (TRT) treatment to consumers across the U.S via its proprietary telehealth platform. MangoRx intends to market PRIME to those male individuals who are both a) currently on some alternative form of TRT treatment, such as topicals and other invasive injectables or pellets, and b) those experiencing common symptoms associated with low testosterone (Low-T) and seeking an immediate TRT treatment.

Furthermore, the introduction of oral testosterone therapy presents a compelling opportunity to tap into a significant addressable market. By offering an alternative to injectable TRT, oral therapy addresses the concerns of individuals who are hesitant or unwilling to undergo injections. This segment of the market, encompassing those with needle aversion, represents a substantial portion of the population and presents a compelling case for the viability and potential growth of oral testosterone therapy.

PRIME represents a critical expansion into a new vertical with massive market potential and very little competition on the consumer side, while remaining completely consistent with MangoRx?s established identity as a company committed to providing new and innovative pharmaceutical based solutions helping men achieve optimal performance in all areas of life. With the Company?s established marketing and telemedicine infrastructure in place, MangoRx is hitting the ground running to take PRIME to patients in need across the country. All orders will be reviewed and, pending approval, fulfilled, then discreetly shipped via MangoRx?s URAC accredited mail order partner pharmacy directly to the patient?s doorstep.